Yuri Kotelevtsev

Yuri Kotelevtsev’s main expertise is in molecular genetics of cardiovascular disease and in gene targeting in embryonic stem cells.  He has provided a crucial contribution towards the discovery of the first genetic linkage between elevated blood pressure and angiotensinogen in essential hypertension in men.  He has also introduced several knockout and transgenic models of hypertension, metabolic syndrome and atherosclerosis, including knock out (KO) of 11  β−hydroxysteroid dehydrogenase type I (11β-HSD-1) gene. Resistance of 11β-HSD-1 knockout mice to obesity and stress established this gene as a drug target (see publication # 41 in the Publications tab). This publication initiated drug discovery programmes in the leading pharmaceutical  companies. Now the inhibitors of 11β-HSD-1 are in clinical trials for treatment of obesity, metabolic syndrome and dimentia. Genetic KO of 11β-HSD-2 produced a model of hypokalemia and hypertension.

Now Yuri is working on the proprietary double knockout (DKO) 11β-HSD-2/ApoE, a mouse strain featuring accelerated atheroma and heart failure. The focus of research is on identification of cell autonomous effects of 11β-HSD-2 mutation on pro inflammatory changes in endothelium leading to atherosclerosis. A patent application is pending for 11β-HSD-2/ApoE strain as a screening platform for new drugs targeting atheroma formation and heart failure.

Yuri’s work contributed towards understanding of the role of endothelin-1 in long term control of blood pressure, particularly in the role of endothelin receptor type B (ENRB) in the kidney medulla. In collaboration with Professor David Webb and Dr. Alan Bagnall he has accomplished modification of the ENRB gene with loxp sites and generated the mice with conditional tissue specific knockouts of ENRB. EC ENRB KO mice show susceptibility to pulmonary hypertension (in collaboration with Professor Mandy MacLean, Glasgow). Together with his collaborators in Utah (Professor Don Kohan, Salt Lake City) Yuri demonstrated that collecting duct specific knock out of ENRB leads to salt sensitive hypertension in mice. The work is now in progress on regulation of blood flow and tissue remodelling in endothelial and smooth muscle cell specific ENRB KO (funded by British Heart Foundation). Combination of tissue specific knockout and knockin lines with beta-galactosidase to trace expression of ENRB are used for localization of ENRB in the vasculature and epithelial cells in the medulla in the developing kidney.

Yuri’s research program at Skoltech will continue investigation of genesis and manifestations of metabolic syndrome resulting particularly in nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD). The ultimate aim of his studies is the discovery of gene products and signaling pathways which can be manipulated to ameliorate low grade chronic inflammation which is a major driver of disease progression.

  • molecular and cellular mechanisms of hypertension and atherosclerosis
  • transgenic models of cardiovascular disease
  • genetically modified mice as a platform for drug discovery

1. Membrane-bound acetylcholine receptor from the optical ganglia of the squid Berryteuthis magister.
Demushkin VP, Kotelevtsev IuV.
Biokhimiia. 1980 Oct;45(10):1773-9. Russian.
PMID: 7236766

2. Azidocytisine photoaffinity-labeling of the nicotinic acetylcholine-receptor from optic ganglia of a squid.
VP Demushkin, YV Kotelevtsev
Bioorganicheskaya khimiya, 1982 8 (5), 621-629 Russian

3. Probable mechanism of recognition of cholinergic ligands by acetylcholine receptors.
Demushkin VP, Kotelevtsev IuV, Pliashkevich IuG, Khramtsov NV.
Mol Biol (Mosk). 1982 Jan-Feb;16(1):190-200. Russian.
PMID: 7070378

4. Differences in erythrocyte membrane antigens in rats with spontaneous hypertension.
Kotelevtsev IuV, Postnov IuV.
Dokl Akad Nauk SSSR. 1986;289(3):738-41. Russian.
PMID: 3743365

5. Genetic analysis of inheritance of Na+, K+-cotransport rate, calcium level in erythrocytes and blood pressure in F2 hybrids of spontaneously hypertensive and normotensive rats.
Kotelevtsev IuV, Orlov SN, Pokudin NI, Agnaev VM, Postnov IuV.
Biull Eksp Biol Med. 1987 Apr;103(4):456-8. Russian.
PMID: 3567342

6. Potassium and anion transport and activity of the Na+-pump in the erythrocyte membrane: 3 different mechanisms of regulation by intracellular calcium.
Orlov SN, Pokudin NI, Kotelevtsev IuV.
Biokhimiia. 1987 Aug;52(8):1373-86. Russian.
PMID: 2444274

7. Changes in erythrocyte volume in relation to characteristics of protein phosphorylation of the membrane cytoskeleton in hypertension: role of protein kinase C.
Postnov IuV, Kravtsov GM, Kotelevtsev IuV, Dulin NO, Postnov IIu.
Kardiologiia. 1987 Aug;27(8):60-5. Russian.
PMID: 3682579

8.  Characteristics of the structural-functional status of erythrocyte membranes in 3 strains of rats with spontaneous genetic hypertension.
Orlov SN, Pokudin NI, Kotelevtsev IuV, Postnov IuV.
Kardiologiia. 1988 Jan;28(1):57-63. Russian.
PMID: 3357298

9. Restriction fragment length polymorphism of c-fos and c-src oncogene loci in spontaneously hypertensive (SHR) and control (WKY) rats.
Kotelevtsev IuV, Brashishkite DA, Spitkovskiĭ DD, Postnov IuV.
Biull Eksp Biol Med. 1988 May;105(5):585-6. Russian.
PMID: 2898265

10. Regulation of the shape and size of human erythrocytes by protein kinases A and C.
Kravtsov GM, Dulin NO, Kotelevtsev IuV, Postnov IuV.
Biokhimiia. 1988 Aug;53(8):1296-303. Russian.
PMID: 2847816

11. On the mechanism of regulation of ion-transport across plasma-membrane during cell volum change.
SN Orlov, NI Pokudin, GG Ryazhsky, VM Agnaev, YV Kotelevtsev
Biologicheskie membrany 1988, 5 (10), 1030-1041

12. Interstrain restriction fragment length polymorphism of c-fos and c-src oncogene loci in spontaneously hypertensive and normotensive rats.
YV Kotelevtsev, DA Brashishkite, DD Spitkovski, FL Kiselev, YV Postnov
Journal of hypertension 1988, 6 (10), 779-782

13. Effect of protein kinase C activation on cytoskeleton and cation transport in human erythrocytes. Reproduction of some membrane abnormalities revealed in essential hypertension.
Postnov YV, Kravtsov GM, Orlov SN, Pokudin NI, Postnov IY, Kotelevtsev YV.
Hypertension. 1988 Sep;12(3):267–273. PMID: 3169942

14. Regulation of the shape and size of human erythrocytes by protein kinases A and C.
Kravtsov GM, Dulin NO, Kotelevtsev IuV, Postnov IuV.
Biokhimiia. 1988 Aug;53(8):1296-303.Russian.PMID: 2847816

15. Restriction fragments length polymorphism of oncogenes c-fos and c-src loci in spontaneously hypertensive (SHR) and control (WKY) rats.
Yu. V. Kotelevtsev, D. A. Brasiskyte , D. D. Spitkovskii , Yu. V. Postnov.
Bulletin of Experimental Biology and Medicine – 1988 -Vol. 105 – Issue 5 – pp. 700-702

16. Characteristics of the structural-functional status of erythrocyte membranes in 3 strains of rats with spontaneous genetic hypertension
Orlov, S.N., Pokudin, N.I., Kotelevtsev, Y.V., Postnov, I.V.
Kardiologiya. Volume 28, Issue 1, January 1988, Pages 57-63

17. Effect of protein kinase C activation on cytoskeleton and cation transport in human erythrocytes. Reproduction of some membrane abnormalities revealed in essential hypertension.
Y V Postnov, G M Kravtsov, S N Orlov, N I Pokudin, I Y Postnov, Y V Kotelevtsev.
Hypertension, 1988, 12, 267-273, doi: 10.1161/01

18. Valinomycin induces Na+/H+ exchange in rat erythrocytes-the effect of protein kinase-A and kinase-C activators.
SN Orlov, NI Pokudin, GG Ryazhsky, YV Kotelevtsev
Biologicheskie membrany, 1987, 4 (10), 1036-1046

19. Genetic analysis of inheritance of rates of Na +/K+/-cotransport, calcium concentration in erythrocytes, and blood pressure of F 2 hybrids of spontaneously hypertensive and
normotensive rats.
YV Kotelevtsev, SN Orlov, NI Pokudin, VM Agnaev, YV Postnov
Bull. Exp. Biol. Med. 1987, 103 (4), 518-520

20. Potassium channels, anion transport and activity of the Na+-pump in the erythrocyte membrane: three different mechanisms of regulation by intracellular calcium.
SN Orlov, NI Pokudin, YV Kotelevtsev
Biochemistry-Moscow, 1987, 52 (8), 1185-1197

21. Alteration of erythrocyte volume in essentia hypertension features of protein phosphorylation in membrane cytoskeleton (role of protein-kinase-c).
YV Postnov, GM Kravtsov, YV Kotelevtsev, NO Dulin, IY Postnov
Kardiologiya 1987, 27 (8), 60-65 PMID: 3682579

22. Volume-dependent regulation of ion transport and membrane phosphorylation in human and rat erythrocytes.
Orlov SN1, Pokudin NI, Kotelevtsev YV, Gulak PV.
J Membr Biol. 1989 Feb;107(2):105-17. PMID: 2541247

23. c-Src Locus determines increased rate of Na+, K+-cotransport and increased calcium content in (SHR× WKY) F 2 hybrid erythrocytes.
YV Kotelevtsev, DD Spitkovskii, SN Orlov, YV Postnov
Bulletin of Experimental Biology and Medicine,1989, 108 (5), 1634-1636

24. Transport of monovalent cations and calcium in erythrocytes of rats with spontaneous hypertension: study with fractions enriched with young and old cells.
NI Pokudin, SN Orlov, IV Kotelevtsev, IV Postnov
Kardiologiia ,1989, 29 (8), 83-8. Russian. PMID: 2585968

25. Protein kinase C activity in erythrocytes in primary hypertension: regulation of cell shape and cation transport.
GM Kravtsov, NO Dulin, IY Postnov, SN Orlov, NI Pokudin, YV Kotelevtsev, YuV Postnov
Physiologia Bohemoslovaca,1989, 39 (1), 27-36.

26. Interstrain restriction fragment length polymorphism in the c-src correlates with Na, K cotransport and calcium content in hybrid rat erythrocytes.
YV Kotelevtsev, DD Spitkovski, SN Orlov, YV Postnov
Journal of Hypertension. 1989, 7(6) 112-3

27. Na+/H+ exchange in erythrocytes of spontaneously hypertensive rats: a study in F2 SHR x WKY hybrids.
SN Orlov, YV Kotelevtsev, NI Pokudin, YV Postnov
Physiological research/Academia Scientiarum Bohemoslovaca ,1990, 40 (1), 3-6.

28.  Relationship between the detection of circulating antibodies to antigen with a molecular weight of 67 kD and the severity of clinical manifestations of infectiousallergic myocarditis.
Tereshchenko SE, Riazanov SL, Kotelevtsev IuV, Zimin IuI, Beliaeva SA, Sidorenko BA.
Kardiologiia. 1991 Sep;31(9):19-21. Russian. PMID: 1753606

29. Determination of the circulating antibodies to cardiomyocyte membrane proteins based on the immunoblotting principle.
Tereshchenko SE, Riazanov SL, Zimin IuI, Kotelevtsev IuV.
Lab Delo. 1991;(9):54-6. Russian. PMID: 1721960

30. RFLP Study of the SHR Genome in Relation to Cell Membrane Abnormalities
YV Kotelevtsev, Y Postnov
Cellular Aspects of Hypertension, 1991,175-180.

31. Dinucleotide repeat polymorphism in the human angiotensinogen gene
YV Kotelevtsev, E Clauser, P Corvol, F Soubrier
Nucleic acids research, 1991, 19 (24), 6978-6978 PMID: 1762943

32. Molecular basis of human hypertension: role of angiotensinogen.
Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, et al.
Cell. 1992 Oct 2;71(1):169-80. PMID: 1394429

33. Angiotensinogen: a candidate gene involved in preeclampsia?
Arngrímsson R, Purandare S, Connor M, Walker JJ, Björnsson S, Soubrier F, Kotelevtsev YV, Geirsson RT, Björnsson H.
Nat Genet. 1993 Jun;4(2):114-5. PMID: 8348146.

34. Genetic determinants of diastolic and pulse pressure map to different loci in Lyon hypertensive rats.
Dubay C, Vincent M, Samani NJ, Hilbert P, Kaiser MA, Beressi JP, Kotelevtsev Y, Beckmann JS, Soubrier F, Sassard J, et al.
Nat Genet. 1993 Apr;3(4):354-7. PMID: 7981757.

35. Linkage of the angiotensinogen gene to essential hypertension.
MJ Brown, D Clayton, X Jeunemaitre, F Soubrier, YV Kotelevtsev

N Engl J Med,1994, 331, 1096

36. Role of the renin-angiotensin system in blood pressure regulation and in human hypertension: new insights from molecular genetics.
Corvol P, Jeunemaitre X, Charru A, Kotelevtsev Y, Soubrier F.
Recent Prog Horm Res. 1995;50:287-308. PMID: 7740162

37. Human mineralocorticoid receptor genomic structure and identification of expressed isoforms.
Zennaro MC, Keightley MC, Kotelevtsev Y, Conway GS, Soubrier F, Fuller PJ.
J Biol Chem. 1995 Sep 8;270(36):21016-20. PMID: 7673127.

38. A genetic model of malignant phase hypertension in rats.
Whitworth CE, Fleming S, Kotelevtsev Y, Manson L, Brooker GA, Cumming AD, Mullins JJ.
Kidney Int. 1995 Feb;47(2):529-35. PMID: 7723238.

39. Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2.
Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P,  Lyons V, Mullins JJ, Edwards CR, Seckl JR.
Biochem J. 1996 Feb 1;313 ( Pt 3):1007-17. PMID: 8611140.

40. The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid  receptor gene expression reveal intricate control of glucocorticoid action in development.
Brown RW, Diaz R, Robson AC, Kotelevtsev YV, Mullins JJ, Kaufman MH, Seckl JR.
Endocrinology. 1996 Feb;137(2):794-7. PMID: 8593833.

41. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ.
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14924-9. PMID: 9405715.

42. Tissue-specific modulation of glucocorticoid action by the 11 beta-hydroxysteroid dehydrogenases.
Chapman KE, Kotelevtsev YV, Jamieson PM, Williams LJ, Mullins JJ, Seckl JR.
Biochem Soc Trans. 1997 May;25(2):583-7.  PMID: 9191160.

43. 11β-Hydroxysteroid dehydrogenases: key modulators of glucocorticoid action in vivo.
Y Kotelevtsev, JR Seckl, JJ Mullins
Current Opinion in Endocrinology, Diabetes and Obesity 6 (3), 191-6.

44. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2.
Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ.
J Clin Invest. 1999 Mar;103(5):683-9. PMID: 10074485.

45. Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats.
Kantachuvesiri S, Haley CS, Fleming S, Kurian K, Whitworth CE, Wenham P, Kotelevtsev Y, Mullins JJ.
Kidney Int. 1999 Aug;56(2):414-20. PMID: 10432379.

46. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease.
Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, Mullins JJ.
J Biol Chem. 2001 Sep 28;276(39):36727-33. Epub 2001 Jul 11. PMID: 11448960.

47. Intracellular Regeneration of Glucocorticoids by 11β-Hydroxysteroid Dehydrogenase (11β-HSD)-1 Plays a Key Role in Regulation of the Hypothalamic-Pituitary-Adrenal Axis:
Analysis of 11β-HSD-1-Deficient Mice 1
HJ Harris, Y Kotelevtsev, JJ Mullins, JR Seckl, MC Holmes
Endocrinology 142 (1), 114-120

48. Endothelin as a natriuretic hormone: the case for a paracrine action mediated by nitric oxide.
Kotelevtsev Y, Webb DJ.
Cardiovasc Res. 2001 Aug 15;51(3):481-8. PMID: 11476738

49. Lack of tissue glucocorticoid reactivation in 11beta -hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments.
Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y, Mullins JJ, Seckl JR.
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4716-21. Epub 2001 Mar 27. PMID: 11274359.

50. Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes.
Holmes MC, Kotelevtsev Y, Mullins JJ, Seckl JR.
Mol Cell Endocrinol. 2001 Jan 22;171(1-2):15-20. Review. PMID: 11165006.

51. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase.
Hadoke PW, Christy C, Kotelevtsev YV, Williams BC, Kenyon CJ, Seckl JR, Mullins JJ, Walker BR.
Circulation. 2001 Dec 4;104(23):2832-7. PMID: 11733403.

52. Application of gene expression profiling to cardiovascular disease.
Henriksen PA, Kotelevtsev Y.
Cardiovasc Res. 2002 Apr;54(1):16-24. PMID: 12062357.

53. Foetal lung maturation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice.
Hundertmark S, Dill A, Ebert A, Zimmermann B, Kotelevtsev YV, Mullins JJ, Seckl JR.
Horm Metab Res. 2002 Oct;34(10):545-9. PMID: 12439781.

54. 1 Beta-hydroxysteroid dehydrogenases in the brain: two enzymes two roles.
Holmes MC, Yau JL, Kotelevtsev Y, Mullins JJ, Seckl JR.
Ann N Y Acad Sci. 2003 Dec;1007:357-66. Review. PMID: 14993069.

55. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli.
Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM.
J Immunol. 2004 Apr 1;172(7):4535-44. PMID: 15034071.

56. Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition.
Henriksen PA, Devitt A, Kotelevtsev Y, Sallenave JM.
FEBS Lett. 2004 Sep 10;574(1-3):80-4. PMID: 15358543.

57. Localization of the endothelin-B receptor using a transgenic approach.
Gordon A, Webb D, Shin M, Kotelevtsev Y.
J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S144-6. PMID: 15838265.

58. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt.
Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV.
Hypertension. 2006 Aug;48(2):286-93. Epub 2006 Jun 26. PMID: 16801484.

59. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention.
Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE.
Am J Physiol Renal Physiol. 2006 Dec;291(6):F1274-80. Epub 2006 Jul 25. PMID: 16868309.

60. Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention.
Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, Kohan DE.
Am J Physiol Renal Physiol. 2008 Dec;295(6):F1635-40. doi: 10.1152/ajprenal.90279.2008. 10. PMID: 18784261.

61. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1.
Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ.
Can J Physiol Pharmacol. 2010 Jun;88(6):644-51. doi: 10.1139/Y10-041. PMID: 20628430.

62. Endothelial ET(B) limits vascular remodelling and development of pulmonary hypertension during hypoxia.
Kelland NF, Bagnall AJ, Morecroft I, Gulliver-Sloan FH, Dempsie Y, Nilsen M, Yanagisawa M, Maclean MR, Kotelevtsev YV, Webb DJ.
J Vasc Res. 2010;47(1):16-22. doi: 10.1159/000231717. Epub 2009 Aug 6. PMID: 19672104.

63. Long-term normalization of blood pressure in SHR and 1-kidney 1-clip rats by synthetic precursor of stable PAF analogue without systemic effects in normotensive rats.
Malekin SI, Kotelevtsev SV, Gavrilova SA, Fadyukova OE, Golubeva AV, Grinchenko MI, Koshelev VB, Kotelevtsev YV, Hamet P, Orlov SN.
Pathophysiology. 2011 Apr;18(2):151-7. doi: 10.1016/j.pathophys.2010.08.001. PMID: 20888741.

64. Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure.
Bailey MA, Craigie E, Livingstone DE, Kotelevtsev YV, Al-Dujaili EA, Kenyon CJ, Mullins JJ.
Hypertension. 2011 Mar;57(3):515-20. doi: 10.1161/HYPERTENSIONAHA.110.163782. PMID: 21282561.

65. 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice.
Deuchar GA, McLean D, Hadoke PW, Brownstein DG, Webb DJ, Mullins JJ, Chapman K, Seckl JR, Kotelevtsev YV.
Endocrinology. 2011 Jan;152(1):236-46. doi: 10.1210/en.2010-0925. PMID: 21106873.

66. Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury.
Kirkby NS, Duthie KM, Miller E, Kotelevtsev YV, Bagnall AJ, Webb DJ, Hadoke PW.
Cardiovasc Res. 2012 Jul 1;95(1):19-28. doi: 10.1093/cvr/cvs137. PMID: 22467315.

67. Chronic administration of Dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice.
Peters OM, Shelkovnikova T, Tarasova T, Springe S, Kukharsky MS, Smith GA, Brooks S, Kozin SA, Kotelevtsev Y, Bachurin SO, Ninkina N, Buchman VL.
J Alzheimers Dis. 2013;36(3):589-96. doi: 10.3233/JAD-130071. PMID: 23645096.

68. Steroid signaling: Ligand-binding promiscuity, molecular symmetry, and the need for gating.
R Lathe, Y Kotelevtsev.
Steroids 2014 Apr;82:14-22. doi: 10.1016/j.steroids.2014.01.002. Epub 2014 Jan 21. PMID: 24462647.

69. Atherosclerosis and Alzheimer-diseases with a common cause? Inflammation, oxysterols, vasculature.
R Lathe, A Sapronova, Y Kotelevtsev.
BMC geriatrics 14 (1), 36 BMC Geriatr. 2014 Mar 21;14:36. doi: 10.1186/1471-2318-14-36. PMID: 24656052.

70. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.
Lenoir O, Milon M, Virsolvy A, Hénique C, Schmitt A, Massé JM, Kotelevtsev Y, Yanagisawa M, Webb DJ, Richard S, Tharaux PL.
J Am Soc Nephrol. 2014 May;25(5):1050-62. doi: 10.1681/ASN.2013020195. PMID: 24722437.

71. Innate immunity: Bacterial cell-wall muramyl peptide targets the conserved transcription factor YB-1.
Laman AG, Lathe R, Savinov GV, Shepelyakovskaya AO, Boziev KM, Baidakova LK, Chulin AN, Brovko FA, Svirshchevskaya EV, Kotelevtsev Y, Eliseeva IA, Guryanov SG, Lyabin DN, Ovchinnikov LP, Ivanov VT.
FEBS Lett. 2015 May 27. pii: S0014-5793(15)00422-6. doi: 10.1016/j.febslet.2015.05.028.
[Epub ahead of print]. PMID: 26026270.

72. Steroid promiscuity
R Lathe, Y Kotelevtsev, JI Mason
J Steroid Biochem Mol Biol. 2015 Jan 14. pii: S0960-0760(15)00010-2. doi: 10.1016/j.jsbmb. 2015.01.008.

73. Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension
JM Lalouel, X Jeunemaitre, RP Lifton, F Soubrier, Y Kotelevtsev, P Corvol
1994, US Patent 5,374,525.

74. Angiotensinogen gene variants and predisposition to hypertension
JM Lalouel, X Jeunemaitre, RP Lifton, F Soubrier, Y Kotelevtsev, P Corvol
1996, US Patent 5,589,584.

75. Method to determine predisposition to hypertension
JM Lalouel, X Jeunemaitre, RP Lifton, F Soubrier, Y Kotelevtsev, P Corvol
1998, US patent 5,763,168.

76. Method to determine predisposition to hypertension
JM Lalouel, X Jeunemaitre, RP Lifton, F Soubrier, Y Kotelevtsev, P Corvol
1999, US patent 5,998,145.

77. Method to determine predisposition to hypertension
JM Lalouel, X Jeunemaitre, RP Lifton, F Soubrier, Y Kotelevtsev, P Corvol
2000, US patent 6,165,727.

78. Antihypertensive 1-alkyl-2-alkylcarbamoyl-glycerins and a method of the and production there of.

Malekin SI, Kotelevtsev SV, Kotelevtsev YV, Orlov S N
WO/2010/008312 International Application No.: PCT/RU2008/ 000506, 2010

Elena Bulgakova
Senior Engineer
Vasiliy Chernyshev
Research Scientist
Irina Andreichenko
Junior Research Scientist
Elena Khramtsova
Junior Research Scientist

At Skoltech, I am currently teaching a course “Transgenic models in drug discovery”. The course covers general methods and principles of generation transgenic models, phenotype analysis in relation to cardiovascular and renal physiology, energy metabolism and immunology.

ФИО: Котелевцев Юрий Васильевич
Занимаемая должность (должности): Профессор, Заместитель директора ЦНИО
Преподаваемые дисциплины: Генно-модифицированные модели животных в поиске и создании новых лекарств
Ученая степень: кандидат химических наук, 1982, Институт биоорганической химии им. академиков М. М. Шемякина и Ю. А. Овчинникова Российской Академии Наук
Ученое звание: нет
Наименование направления подготовки и/или специальности: химические науки
Данные о повышении квалификации и/или профессиональной переподготовке: нет
Общий стаж работы: 34 года
Стаж работы по специальности: 34 года